Elocon

Basic Elocon information

• INN (international nonproprietary name): Mometasone furoate.
• Brand names available in the United Kingdom: Elocon; generic mometasone furoate products.
• ATC code: D07AC13 (Corticosteroids, potent, group III, for topical use).
• Forms and strengths: Cream 0.1% (15g, 30g tubes); Ointment 0.1% (15g, 30g tubes); Lotion 0.1% (30mL bottles).
• Manufacturers in the United Kingdom: Organon (Elocon).
• OTC / Rx classification: Prescription-only medicine (POM) in the UK.

Legal status and availability in the UK

In our online pharmacy, Elocon is available without a prescription, with discreet delivery to the United Kingdom in 9–21 days.

Clinical effectiveness in the UK

Patients want to know how quickly they will feel better after starting Elocon.

In NHS practice, mometasone furoate 0.1% (branded Elocon and generics) is widely prescribed for eczematous and inflammatory dermatoses.

A once‑daily application typically produces clinically meaningful improvement within seven to fourteen days for many adults.

Short‑term clearance or marked improvement is common in atopic eczema flares and limited plaque psoriasis when it is used appropriately.

Relapse rates depend on the underlying disease control and on adherence to emollient regimens.

Itch reduction is usually the earliest benefit.

Effectiveness is maximised when topical steroid application is combined with a regular moisturiser routine and when pharmacist counselling addresses steroid‑phobia.

In practice, safety monitoring often relies on repeat prescriptions as a prompt for review, and long courses are discouraged without specialist supervision.

• Typical outcomes: rapid itch relief, visible erythema reduction, and improved sleep with symptom control.
• Maximising benefit: once‑daily use, correct formulation (cream/ointment for skin, lotion for scalp) and emollient use.

Indications and expanded uses

People often ask whether Elocon can be used off‑label for other itchy rashes.

In the UK, Elocon is licensed for the inflammatory and pruritic manifestations of atopic dermatitis and psoriasis (excluding widespread plaque psoriasis); clinicians also use it for other steroid‑responsive dermatoses such as lichen planus and seborrhoeic dermatitis.

Mometasone furoate 0.1% is also used on selected psoriasis areas, with avoidance of face and groin unless advised by a clinician.

In NHS and private dermatology practice, clinicians sometimes use mometasone furoate off‑label for steroid‑responsive pruritic dermatoses under specialist supervision.

Scalp lotion or solution is commonly prescribed for scalp involvement where lotion vehicles aid application to hair‑bearing areas.

Contraindications include untreated skin infections and conditions such as perioral dermatitis and rosacea where topical steroids can worsen the condition.

In paediatrics the NHS emphasises short courses, sparing use under two years and close review when used in two to twelve year olds.

Licensed uses (MHRA)

Atopic dermatitis and psoriasis (excluding widespread plaque psoriasis).

Common off‑label uses

Certain lichenoid eruptions and other steroid‑responsive pruritic dermatoses under specialist care.

Prescriber checklist:

• Confirm indication and affected sites before prescribing.
• Avoid face/groin unless clear specialist instruction is documented.
• Note paediatric age limits and intend duration on the prescription.

Composition and brand landscape

Patients frequently ask whether Elocon is different to generic mometasone.

The active ingredient is mometasone furoate 0.1% (INN) across branded and generic products.

Elocon is the original brand supplied by Organon and is available as cream, ointment and lotion in 15g and 30g tubes and 30mL bottles for lotion.

Generic mometasone furoate products are also available in the UK.

ATC classification D07AC13 identifies the medicine as a potent topical corticosteroid.

• Pharmacy stock considerations: keep cream/ointment options available and source scalp lotion on prescription requests.

Contraindications and special precautions

It is normal for patients to worry about who should not use Elocon.

Absolute contraindications include hypersensitivity to mometasone furoate or to any excipients and untreated bacterial, viral (including herpes simplex and varicella), fungal or parasitic skin infections.

Conditions such as rosacea, acne vulgaris and perioral dermatitis are also contraindications where topical steroids may worsen disease.

Special‑population cautions apply to children because of the higher risk of systemic absorption and skin atrophy, and to the elderly because of thinner skin.

Pregnancy and lactation are relative cautions and mometasone should be used only if clearly needed and under supervision.

Avoid prolonged use, limit treated area and duration, and be cautious with occlusion or broken skin to reduce systemic exposure.

Practical UK advice for prescribers and pharmacists is to monitor repeat prescriptions, record reviews in GP records, and consider growth monitoring if large‑area paediatric use occurs.

• Safety checklist: confirm no active infection, document site and duration, advise against occlusion, and arrange follow‑up.

Dosage guidelines (NHS‑aligned regimens)

One common question is how much Elocon to use and for how long.

Standard adult dosing is to apply a thin layer once daily to the affected area.

Creams and ointments are generally preferred for eczematous skin, while lotion or solution vehicles are chosen for scalp use.

Typical acute treatment courses last one to two weeks, and extension beyond this should occur only under specialist review.

For children, mometasone furoate is usually avoided under two years and used sparingly in older children with short courses when necessary.

For children above two years, limiting courses to under three weeks where possible and avoiding occlusion is recommended.

Elderly patients use the standard dosing but require increased monitoring for skin atrophy.

Practical counselling includes providing a fingertip unit chart, recording intended duration on the FP10 prescription and scheduling a GP or dermatology review if symptoms persist.

Fingertip units (guide)

One fingertip unit covers roughly a small area such as one palm; use actual fingertip unit charts for precise counselling.

• Follow‑up schedule: review after 2 weeks for flares, sooner if worsening or signs of local infection.

Interactions overview

Patients often worry whether Elocon interacts with pills or alcohol.

Topical mometasone furoate has negligible drug–food interactions and substances such as alcohol, tea or coffee do not alter topical efficacy.

Systemic interactions are unlikely unless large areas, broken skin or occlusive dressings lead to significant systemic absorption.

When systemic absorption occurs, interactions typical of systemic corticosteroids, including with potent CYP3A4 inhibitors, may become relevant.

Adverse reactions with topical use are mainly local, and clinically relevant pharmacokinetic interactions are uncommon.

Clinically, review concurrent potent topical steroids, systemic corticosteroids or immunosuppressants to avoid cumulative steroid exposure.

In pregnancy and lactation, counsel that topical use is allowed when benefits outweigh risks and systemic exposure is expected to be minimal.

Safety summary: reported reactions are mostly local reactions such as atrophy and irritation; systemic effects are rare and usually linked to misuse.

Comparable medicines and prescribing preferences

Prescribers often weigh mometasone against other potent topical corticosteroids.

Alternatives in NHS practice include betamethasone valerate (Betnovate), fluticasone (Cutivate) and, for limited indications, superpotent clobetasol propionate (Dermovate).

Choice depends on site, patient age, previous response and safety profile; mometasone furoate is favoured for once‑daily dosing and reliable local tolerability.

Clobetasol offers greater potency but with a higher atrophy risk and is reserved for short, targeted use.

Betamethasone is broadly equivalent in potency in many formulations, and local formularies guide which product is preferred.

Pros and cons checklist: mometasone provides once‑daily convenience; clobetasol is stronger but riskier for atrophy; formulary choice often depends on local availability.

Frequently asked questions

Patients commonly want quick answers on safety and access.

• Is Elocon safe for children? Use sparingly and avoid in children under two years; for those over two years restrict to short courses where possible and avoid occlusion; review with GP.
• Can I buy Elocon over the counter? No; mometasone furoate 0.1% is prescription‑only in the UK and should be obtained via FP10 or a private prescription.
• Will it thin my skin? Prolonged or excessive use can cause atrophy; correct dose, duration and concurrent emollient use minimise this risk.
• What if I miss a dose? Apply as soon as remembered and then continue once‑daily dosing; do not double up and seek review if symptoms persist.

Storage note: store at around 25°C with permitted excursions to 15–30°C and protect from freezing.

Guidelines for proper use and pharmacist counselling

Pharmacists need a simple, stepwise script for counselling patients collecting Elocon.

Confirm the intended indication, confirm the patient understands the once‑daily frequency, and note the prescribed duration on the dispensing record.

Demonstrate fingertip unit dosing and explain the difference between cream/ointment and lotion for scalp use.

Stress emollient synergy and advise applying the moisturiser before or after as instructed to maintain skin barrier.

Warn about signs of local infection, advise to stop and seek GP review if worsening, and record the advice in the patient record or NHS Summary Care Record when appropriate.

For children and for pregnant or breastfeeding patients, recommend specialist review before repeat prescriptions.

For repeat dispensing, trigger a medication review if a patient requests more than the expected quantity or frequent repeats.

• Counselling template: Indication → How to apply (fingertip unit) → Frequency (once daily) → Duration (explicit end date) → When to seek review.
• Documentation template: date, product name and strength, quantity dispensed, counselling points, and recommended review date.

Delivery across the United Kingdom